argenx $ARGX

Health Care · NASDAQ

Belgium
$925.70
-16.34 (-1.73%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 22, 2026, the first target we tracked for ARGX.

argenx (ARGX) is trading down at $925.70 (-1.73%) on NASDAQ, as of the latest quote. It operates in the Health Care sector.

IPO: May 18, 2017 · $17.00 offering · NASDAQ

Analyst price targets on ARGX

Current price targets from 3 firms average $1.09k, median $1.2k, ranging from $861 to $1.2k — the average is 17% above the current $926. Each is tracked to its date and scored the same way a member's call is.

3 targets, newest first. Open a row for its source and scoring.

DateOct 22, 2026 FirmBaird RatingNeutral · raises Targetat $876 · $861 -2% Horizonby Oct 2027 StatusOpen

Entry price $876, the close nearest Oct 22, 2026, when the target was reported; the target is -2% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 22, 2027.

Source Baird raises argenx stock price target to $861 on Vyvgart sales Investing.com · Oct 22, 2026 · opens the publisher's site
Baird raised its price target on argenx SE (NASDAQ:ARGX) to $861 from $823 while maintaining a Neutral rating on the stock.
DateOct 22, 2026 FirmJefferies RatingBuy · reiterates Targetat $876 · $1.2k +37% Horizonby Oct 2027 StatusOpen

Entry price $876, the close nearest Oct 22, 2026, when the target was reported; the target is +37% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 22, 2027.

Source Jefferies reiterates argenx stock Buy rating after Q3 beat Investing.com · Oct 22, 2026 · opens the publisher's site
Jefferies reiterated a Buy rating and $1,200 price target on argenx SE
DateOct 22, 2026 FirmStifel RatingBuy · lowers Targetat $876 · $1.2k +37% Horizonby Oct 2027 StatusOpen

Entry price $876, the close nearest Oct 22, 2026, when the target was reported; the target is +37% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 22, 2027.

Source Stifel cuts argenx stock price target on mixed quarter results Investing.com · Oct 22, 2026 · opens the publisher's site
Stifel lowered its price target on argenx SE (NASDAQ:ARGX) to $1,200 from $1,282 while maintaining a Buy rating on the stock.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

argenx revenue & net income history (FY2019–FY2025)

RevenueNet incomeNet margin (right axis, %)
$4.15B$1.72B−$709.6MFY2019 revenue: $78.5MFY2019 net income: −$181.2M · Net margin −231.0%'19FY2020 revenue: $41.2MFY2020 net income: −$608.5M · Net margin −1475.3%'20FY2021 revenue: $497.3MFY2021 net income: −$408.3M · Net margin −82.1%'21FY2022 revenue: $410.7MFY2022 net income: −$709.6M · Net margin −172.8%'22FY2023 revenue: $1.23BFY2023 net income: −$295.1M · Net margin −24.1%'23FY2024 revenue: $2.19BFY2024 net income: $833.0M · Net margin 38.0%'24FY2025 revenue: $4.15BFY2025 net income: $1.29B · Net margin 31.1%'25−17.1%0%25%50%75%100%FY2019 net margin: −231.0% (off the scale, which stops at −17.1%)FY2020 net margin: −1475.3% (off the scale, which stops at −17.1%)FY2021 net margin: −82.1% (off the scale, which stops at −17.1%)FY2022 net margin: −172.8% (off the scale, which stops at −17.1%)FY2023 net margin: −24.1% (off the scale, which stops at −17.1%)FY2024 net margin: 38.0%FY2025 net margin: 31.1%
argenx annual financial statements
FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$78.5M$41.2M$497.3M$410.7M$1.23B$2.19B$4.15B
Growth (year over year)—−47.4%+1105.7%−17.4%+198.6%+78.6%+89.6%
Gross profit———$381.3M$1.11B$1.96B$3.70B
Gross margin———92.8%90.4%89.6%89.1%
Operating income−$198.9M−$477.6M−$348.7M−$720.3M−$425.0M−$21.7M$1.05B
Operating margin−253.5%−1158.1%−70.1%−175.4%−34.7%−1.0%25.4%
Net income−$181.2M−$608.5M−$408.3M−$709.6M−$295.1M$833.0M$1.29B
Net margin−231.0%−1475.3%−82.1%−172.8%−24.1%38.0%31.1%
EPS (diluted)−$4.69−$13.40−$7.99−$13.05−$5.16$12.78$19.57
Balance sheet
Cash and equivalents$372.2M$1.22B$1.33B$800.7M$2.05B$1.50B$3.49B
Total assets$1.61B$2.28B$2.85B$3.13B$4.54B$6.20B$8.68B
Total liabilities$429.8M$605.4M$316.1M$320.6M$445.0M$704.2M$1.36B
Shareholders' equity$1.18B$1.67B$2.53B$2.81B$4.10B$5.50B$7.32B
Cash flow
Operating cash flow$151.6M−$398.5M−$606.8M−$862.8M−$420.3M−$82.7M$685.2M
Capital expenditure$1.80M$1.07M$3.62M$837.0K$812.0K$1.80M$6.17M
Free cash flow$149.8M−$399.5M−$610.4M−$863.6M−$421.1M−$84.5M$679.0M

From argenx's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

argenx in the news

Nov 17, 2026 PR Newswire Cradle's Antibody Discovery Platform for Autoimmune Diseases Supports Scientific Mission of argenx
Nov 12, 2026 PR Newswire INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Nov 10, 2026 Investing.com argenx at 3rd Annual Guggenheim Healthcare Innovation Conference: growth broadens
Nov 9, 2026 Investing.com Why is argenx stock surging today?
Nov 9, 2026 Investing.com Argenx to acquire biotech firm Unnatural Products for $1.15 billion
Show 5 older stories
Nov 9, 2026 GlobeNewswire argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
Nov 7, 2026 GlobeNewswire argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
Oct 22, 2026 Investing.com Baird raises argenx stock price target to $861 on Vyvgart sales Target
Oct 22, 2026 Investing.com Jefferies reiterates argenx stock Buy rating after Q3 beat Target
Oct 22, 2026 Investing.com Stifel cuts argenx stock price target on mixed quarter results Target

About argenx

Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.

Source: Wikipedia — Argenx

Headquarters
Zwijnaarde, Belgium From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →